Ifosfamide

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Ifosfamide
Generic name
IFOSFAMIDE
Manufacturer
Meitheal Pharmaceutical Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
ee600728-df69-4e61-9c94-5ef3801b80ad
SPL ID
6191d3ef-393a-4003-abad-634087bd20de
Version
1
Effective date
2026-10-02
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:31:30
Harmonized routes table
Harmonized routes
INTRAVENOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY • Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle [see Warnings and Precautions (5.1) ] . • Encephalopathy can be severe and may result in death. Monitor for CNS toxicity and discontinue treatment for encephalopathy [see Warnings and Precautions (5.2) ] . • Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna [see Warnings and Precautions (5.3) ] . WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY See full prescribing information for complete boxed warning. Myelosuppression can be severe and lead to fatal infections ( 5.1 ) Encephalopathy can be severe and may result in death ( 5.2 ) Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be severe. ( 5.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Myelosuppression: Monitor blood counts prior to treatment, during treatment, and as clinically indicated. ( 5.1 ) Encephalopathy: Monitor for signs and symptoms of CNS toxicity during and after ifosfamide injection treatment. Dose interruption or permanent discontinuation may be required based on individual safety and tolerability. ( 5.2 ) Nephrotoxicity and Urotoxicity: Monitor signs and symptoms. Monitor serum and urine chemistries. ( 2.1 , 5.3 ) Cardiotoxicity: Arrhythmias, other ECG changes, and cardiomyopathy can occur and result in death. Cardiotoxicity is dose dependent and the risk is increased in patients with preexisting cardiac, treatment with other cardiotoxic agents, radiation, and renal impairment. ( 5.4 ) Pulmonary toxicity: Interstitial pneumonitis, pulmonary fibrosis, and pulmonary toxicity with fatal outcomes can occur. Monitor for signs and symptoms of pulmonary toxicity and treat as clinically indicated. ( 5.5 ) Secondary malignancies can occur. ( 5.6 ) Veno-occlusive Liver Disease can occur. ( 5.7 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. ( 5.8 , 8.1 , 8.3 ) Infertility: Can impair male and female reproductive function. ( 5.9 ) Anaphylactic/anaphylactoid reactions have been reported. ( 5.10 ) 5.1 Myelosuppression Ifosfamide injection can cause myelosuppression that results in severe or fatal infections including sepsis or septic shock. Ifosfamide-induced myelosuppression includes leukopenia, neutropenia, thrombocytopenia (with bleeding events), and anemia. The nadir of the leukocyte count usually occurs during the second week after administration of ifosfamide injection. The risk of myelosuppression is dose-dependent and increased in patients with reduced renal function, bone marrow metastases, prior radiation, and concomitant or prior therapy with other cytotoxic agents. Monitor complete blood counts, including leukocytes, neutrophils, platelets, and hemoglobin prior to each administration of ifosfamide injection, at appropriate intervals during treatment, and as clinically indicated. Myelosuppression may require dosage delays. Avoid administration of ifosfamide injection to patients with a WBC count below 2000/µL, a platelet count below 50,000/µL, or when signs or symptoms of active infection or severe immunosuppression are present. 5.2 Encephalopathy Ifosfamide injection can cause encephalopathy which may be fatal. Signs and symptoms may include confusion, somnolence, coma, hallucination, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, and seizures. Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use. Signs and symptoms may occur or recur within hours to days after administration of ifosfamide injection. Continue supportive care until complete resolution of CNS signs and symptoms. Monitor for signs and symptoms of encephalopathy during and after ifosfamide injection treatment. Dose interruption or permanent discontinuation may be required based on individual safety and tolerability. Consider methylene blue for treatment of encephalopathy. 5.3 Nephrotoxicity and Urotoxicity Ifosfamide injection can cause severe or fatal nephrotoxicity and urotoxicity including glomerular or tubular dysfunction, tubular necrosis, renal parenchymal necrosis, acute renal failure, chronic renal failure, and hemorrhagic cystitis (requiring blood transfusion). Tubular damage may occur up to years after cessation of ifosfamide injection treatment. The risk of nephrotoxicity is increased in patients with renal impairment or reduced nephron reserve. Hemorrhagic cystitis is dose-dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment. Evaluate glomerular and tubular kidney function before treatment with ifosfamide injection, during ifosfamide injection treatment, and as clinically indicated. Monitor serum and urine chemistries (including phosphorus and potassium) and urinary sediment for the presence of erythrocytes or other signs of nephrotoxicity. Signs and symptoms may include a decrease in glomerular filtration rate, increased serum creatinine, proteinuria, enzymuria, cylindruria, aminoaciduria, phosphaturia, glycosuria, osteomalacia, tubular acidosis, Fanconi syndrome, and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Before starting treatment, exclude or correct any urinary tract obstructions [see Contraindications ( 4 )] . During or immediately after administration, provide oral or intravenous fluid to force dieresis to reduce the risk of urinary tract toxicity. Administer mesna with ifosfamide injection to reduce the incidence and severity of urotoxicity [see Dosage and Administration ( 2.1 )] . Obtain a urinalysis prior to each dose of ifosfamide injection. Avoid administration of ifosfamide injection in patients with active urinary tract infections. If microscopic hematuria (greater than 10 RBCs per high power field) is present, then withhold administration of ifosfamide injection until complete resolution. Further administration of ifosfamide injection should be given with vigorous oral or parenteral hydration. Dosage interruption or permanent discontinuation may be required based on individual safety and tolerability. 5.4 Cardiotoxicity Ifosfamide injection can cause severe or fatal cardiotoxicity including any of the following: Supraventricular or ventricular arrhythmias, including atrial/supraventricular tachycardia, atrial fibrillation, pulseless ventricular tachycardia Decreased QRS voltage and ST-segment or T-wave changes Toxic cardiomyopathy leading to heart failure with congestion and hypotension Pericardial effusion, fibrinous pericarditis, and epicardial fibrosis Cardiotoxic effects are dose-dependent and the risk is increased in patients with cardiac disease, prior or concomitant treatment with other cardiotoxic agents, radiation of the cardiac region, and renal impairment. 5.5 Pulmonary Toxicity Ifosfamide injection can cause severe or fatal pulmonary toxicities including interstitial pneumonitis, pulmonary fibrosis, and respiratory failure. Monitor for signs and symptoms of pulmonary toxicity and treat as clinically indicated. 5.6 Secondary Malignancies The incidence of secondary malignancies is increased in patients treated with ifosfamide injection-containing regimens. Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. 5.7 Veno-occlusive Liver Disease Veno-occlusive liver disease has been reported with chemotherapy that included ifosfamide. 5.8 Embryo-Fetal Toxicity Based on mechanism of action and human and animal data, ifosfamide injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1) , Clinical Pharmacology ( 12.1 ) and Nonclinical Toxicology ( 13.1 )] . Fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. Ifosfamide is genotoxic and mutagenic in male and female germ cells. Embryotoxic and teratogenic effects have been observed in mice, rats and rabbits at doses 0.05 to 0.075 times the human dose. Advise pregnant women and females of reproductive potential of the potential risk to the fetus [see Use in Specific Populations ( 8.1 )] . Verify the pregnancy status of females of reproductive potential prior to initiation of ifosfamide injection. Advise females of reproductive potential to use effective contraception during treatment with ifosfamide injection and for up to 12 months after completion of therapy. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ifosfamide injection and for 6 months after completion of therapy [see Use in Specific Populations ( 8.1 , 8.3 )]. 5.9 Infertility Male and female reproductive function and fertility may be impaired in patients treated with ifosfamide injection. Ifosfamide interferes with oogenesis and spermatogenesis. Amenorrhea, azoospermia; and sterility in both sexes have been reported. Development of sterility appears to depend on the dose of ifosfamide, duration of therapy, and state of gonadal function at the time of treatment. Sterility may be irreversible in some patients. Advise patients on the potential risks for infertility [see Use in Specific Populations ( 8.3 and 8.4 )] . 5.10 Anaphylactic/Anaphylactoid Reactions and Cross-sensitivity Anaphylactic/anaphylactoid reactions have been reported in association with ifosfamide. Cross-sensitivity between oxazaphosphorine cytotoxic agents has been reported. 5.11 Impairment of Wound Healing Ifosfamide may interfere with normal wound healing.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common (≥ 10%) adverse reactions were alopecia, nausea/vomiting, hematuria, leukopenia, anemia, CNS toxicity, infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceutical Inc. at 1-888-808-5529 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted from widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The adverse reactions in Table 2 below are based on 30 publications describing clinical experience with fractionated administration of ifosfamide as a single agent with a total dose of 4 to 12 g/m 2 per course. Table 2: Adverse Reactions in Patients Treated with Single Agent Ifosfamide Injection Adverse Reaction Single Agent Ifosfamide Injection % (number of patients) Skin and Subcutaneous Tissue Disorders Alopecia 90% (540/603) Dermatitis 0.08% (1/1317) Papular rash 0.08% (1/1317) Gastrointestinal Disorders Nausea/Vomiting 47% (443/964) Diarrhea 0.7% (9/1317) Stomatitis 0.3% (4/1317) Renal and Urinary Disorders Hemorrhagic cystitis 1 Hematuria - without mesna 44% (282/640) - with mesna 21% (33/155) Macrohematuria - without mesna 11% (66/594) - with mesna 5% (5/97) Renal dysfunction 2 -- Renal structural damage 3 -- Blood and Lymphatic System Disorders Leukopenia 4 (any) -- Leukopenia <1 x 10 3 /µL 44% (267/614) Anemia 6 38% (202/533) Thrombocytopenia 5 (any) -- Thrombocytopenia, 50 x 10 3 /µL 4.8% (35/729) Nervous System Disorders Central nervous system toxicity 7,8 15% (154/1001) Peripheral neuropathy 0.4% (5/1317) Infections and Infestations Infection 10% (112/1128) General Disorders and Administration Site Conditions Phlebitis 9 2.8% (37/1317) Neutropenic fever 10 1% (13/1317) Fatigue 0.3% (4/1317) Malaise Unable to calculate Hepatobiliary Disorders Hepatotoxicity 11 1.8% (22/1190) Metabolism and Nutrition Disorders Anorexia 1.1% (15/1317) Cardiac Disorders Cardiotoxicity 12 0.5% (7/1317) Vascular Disorders Hypotension 13 0.3% (4/1317) 1 Includes dysuria and pollakiuria 2 Includes acute renal failure, irreversible renal failure (fatal outcomes) serum creatinine increased, BUN increased, creatinine clearance decreased, metabolic acidosis, anuria, oliguria, glycosuria, hyponatremia, uremia, creatinine clearance increased 3 Includes acute tubular necrosis, renal parenchymal damage, enzymuria, cylindruria, proteinuria. 4 Includes neutropenia, granulocytopenia, lymphopenia, and pancytopenia 5 Includes severe or fatal bleeding 6 Includes anemia and decrease in hemoglobin/hematocrit 7 Includes coma and death 8 Includes abnormal behavior, affect lability aggression, agitation, anxiety, aphasia, asthenia, ataxia, cerebellar syndrome, cerebral function deficiency, cognitive disorder, coma, confusional state, convulsions, cranial nerve dysfunction, depressed state of consciousness, depression, disorientation, dizziness, electroencephalogram abnormal, encephalopathy, flat affect, hallucinations, headache, ideation, lethargy, memory impairment, mood change, motor dysfunction, muscle spasms, myoclonus, progressive loss of brainstem reflexes, psychotic reaction, restlessness, somnolence, tremor, urinary incontinence 9 Includes phlebitis and irritation of the venous walls 10 Includes granulocytopenic fever 11 Includes increased serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), alkaline phosphatase, gamma-glutamyltransferase (GGT) and lactate dehydrogenase (LDH) 12 Includes severe or fatal congestive heart failure, tachycardia, pulmonary edema 13 Includes shock and death 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Ifosfamide injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic Disorders : agranulocytosis, febrile bone marrow aplasia, bone marrow failure, disseminated intravascular coagulation, hemolytic anemia, hemolytic febrile uremic syndrome, methemoglobinemia, neonatal anemia Cardiac Disorders : cardiac arrest*, cardiac failure*, arrhythmia*, cardiomyopathy*, cardiotoxicity, cardiac shock, ejection fraction decreased*, myocardial infarction*, myocarditis*, ventricular fibrillation*, ventricular tachycardia*, angina pectoris, atrial fibrillation, atrial flutter, bradycardia, bundle branch block left, bundle branch block right, congestive cardiomyopathy, electrocardiogram ST – segment abnormal, electrocardiogram QRD complex abnormal, electrocardiogram T-wave inversion, myocardial depression, myocardial hemorrhage, left ventricular failure, premature atrial contractions, palpitations, pericardial effusion, pericarditis, supraventricular extrasystoles, ventricular extrasystoles Congenital Disorders : fetal growth retardation Ear Disorders : deafness, hypoacusis, tinnitus, vertigo Endocrine Disorder : SIADH Eye Disorders : conjunctivitis, eye irritation, vision blurred, visual impairment Gastrointestinal Disorders : abdominal pain, cecitis, colitis, constipation, enterocolitis, ileus, gastrointestinal hemorrhage, mucosal ulceration, pancreatitis, salivary hypersecretion General Disorders and Administrative Site Conditions : multi-organ failure*, chest pain, chills, injection/infusion site reactions (including erythema, inflammation, pain, pruritus, swelling, tenderness), edema, general physical deterioration, mucosal inflammation, pain, pyrexia Hepatobiliary Disorders : hepatic failure*, hepatitis fulminant* cholestasis, cytolytic hepatitis, portal vein thrombosis, veno-occlusive liver disease Immune System Disorders : anaphylactic reaction, angioedema, hypersensitivity reaction, immunosuppression, urticaria Infections : The following manifestations have been associated with myelosuppression and immunosuppression caused by ifosfamide: increased risk for and severity of infections † , pneumonias † , sepsis and septic shock (including fatal outcomes), as well as reactivation of latent infections, including viral hepatitis † , Pneumocystis jiroveci † , herpes zoster, Strongyloides , progressive multifocal leukoencephalopathy † , and other viral and fungal infections. † Severe immunosuppression has led to serious, sometimes fatal, infections Metabolic and Nutrition Disorders : hypocalcemia, hypokalemia, hypophosphatemia, hyperglycemia, metabolic acidosis, polydipsia, tumor lysis syndrome Musculoskeletal and Connective Tissue Disorders : arthralgia, growth retardation, myalgia, muscle twitching, osteomalacia, pain in extremity, rhabdomyolysis, rickets Neoplasms : secondary malignancies*, acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, myelodysplastic syndrome, Non-Hodgkin’s lymphoma, renal cell carcinoma, sarcomas, thyroid cancer Nervous System Disorders : seizure*, asterixis, dysarthria, dysesthesia, extrapyramidal disorder, fecal incontinence, gait disturbance hypothesia, leukoencephalopathy, movement disorder, neuralgia, paresthesia, polyneuropathy, reversible posterior leukoencephalopathy syndrome. Ifosfamide has been reintroduced after neurotoxicity. While some patients did not experience neurotoxicity, others had recurrent, including fatal, events. Psychiatric Disorders : amnesia, bradyphrenia, catatonia, delirium, delusion, echolalia, logorrhea, mania mental status change, mutism, paranoia, panic attack, perseveration Renal and Urinary Disorders : aminoaciduria, diabetes insipidus, enuresis, Fanconi syndrome, feeling of residual urine, nephrogenic phosphaturia, polyuria, tubulointerstitial nephritis Reproductive System and Breast Disorders : amenorrhea, azoospermia, decreased blood estrogen, impairment of spermatogenesis, increased blood gonadotrophin, infertility, oligospermia, ovarian disorder, ovarian failure, ovulation disorder, premature menopause Respiratory, Thoracic, and Mediastinal Disorders : acute respiratory distress syndrome*, pulmonary fibrosis*, pneumonitis*/interstitial lung disease*, pulmonary edema*, pulmonary hypertension*, respiratory failure*, alveolitis allergic, bronchospasm, cough, dyspnea, hypoxia, pleural effusion Skin and Subcutaneous Disorders : erythema, facial swelling, hyperhidrosis, macular rash, nail disorder, palmar-plantar erythrodysesthesia syndrome, petechiae, pruritus, radiation recall dermatitis, rash, skin hyperpigmentation, skin necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis Vascular Disorders : capillary leak syndrome, deep vein thrombosis, flushing, hypertension, pulmonary embolism, vasculitis * Includes fatal outcomes

adverse reactions table

<table width="80%"> <caption>Table 2: Adverse Reactions in Patients Treated with Single Agent Ifosfamide Injection </caption> <tbody> <tr> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> <content styleCode="bold">Adverse Reaction </content> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> <content styleCode="bold"> Single Agent Ifosfamide Injection</content> <content styleCode="bold">%</content> <content styleCode="bold">(number of patients)</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Alopecia</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 90% (540/603)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Dermatitis</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.08% (1/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Papular rash</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.08% (1/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> <content styleCode="bold"> Gastrointestinal Disorders</content> </td> <td styleCode="Botrule Lrule Rrule Toprule"/> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Nausea/Vomiting</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 47% (443/964)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Diarrhea</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.7% (9/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Stomatitis</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center">0.3% (4/1317) </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold"> Renal and Urinary Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Hemorrhagic cystitis<sup>1</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule"/> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> Hematuria </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> - without mesna</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 44% (282/640)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> - with mesna</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 21% (33/155)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> Macrohematuria </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> - without mesna</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 11% (66/594)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> - with mesna</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 5% (5/97)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Renal dysfunction<sup>2</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> --</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Renal structural damage<sup>3</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> --</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">Blood and Lymphatic System Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Leukopenia<sup>4</sup> (any)</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> --</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Leukopenia &lt;1 x 10<sup>3</sup>/&#xB5;L</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 44% (267/614)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Anemia<sup>6</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 38% (202/533)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Thrombocytopenia<sup>5</sup> (any)</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> --</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Thrombocytopenia, 50 x 10<sup>3</sup>/&#xB5;L</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 4.8% (35/729)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">Nervous System Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Central nervous system toxicity<sup>7,8</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 15% (154/1001)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Peripheral neuropathy</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.4% (5/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold"> Infections and Infestations</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Infection</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 10% (112/1128)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Phlebitis<sup>9</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 2.8% (37/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Neutropenic fever<sup>10</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1% (13/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Fatigue</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.3% (4/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Malaise</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> Unable to calculate</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">Hepatobiliary Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Hepatotoxicity<sup>11</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1.8% (22/1190)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">Metabolism and Nutrition Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Anorexia</td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 1.1% (15/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold"> Cardiac Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Cardiotoxicity<sup>12</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.5% (7/1317)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule" colspan="2"> <content styleCode="bold">Vascular Disorders</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule"> Hypotension<sup>13</sup> </td> <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 0.3% (4/1317)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.